LCA1 Gene Therapy Improves Sensitivity, BCVA at Highest Dose
No serious TEAEs have been related to ATSN-101 with data up to 6 months after treatment.
The gene therapy ATSN-101 (Atsena Therapeutics) was well-tolerated and yielded improvements in full-field stimulus testing (FST) and multi-luminance mobility testing (MLMT) in patients with Leber congenital amaurosis (LCA), due to mutations in the GUCY2D gene (LCA1) according to updated data from a phase 1/2 trial (NCT03920007).
Data from the trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, held April 23-27, 2023, in New Orleans, Louisiana, by investigator Christine Nichols Kay, MD, vitreoretinal surgeon and director of Electrophysiology, Retinal Genetics, and Clinical Trials at Vitreoretinal Associates in Gainesville, Florida, and an affiliate assistant professor at the University of South Florida, who also serves as a clinical ophthalmology advisor for Atsena.
“The goal of this phase 1/2 study was to evaluate the safety, tolerability, and efficacy of ascending doses of ATSN-101, a subretinal gene therapy for LCA secondary to mutations in the GUCY2D gene,” Kay and colleagues wrote.
READ MORE: PDE6A-associated Retinitis Pigmentosa Gene Therapy May Cause Loss of Vision in Some Patients
Data from the trial are from 15 patients with a median age of 21 years (range, 12-76), 10 of which are female. These participants received unilateral subretinal injections of ATSN-101 in 3 dose cohorts (1.0 x 1010 vg/eye, 3.0 x 1010 vg/eye, and 1.0 x 1011 vg/eye) with 3 participants each; in the expansion phase 1 adult and 1 pediatric cohort of 3 more patients each were also treated at the highest dose. The phase 1/2 trial is primarily evaluating the incidence of adverse events, while secondary outcomes are evaluating changes in BCVA and sensitivity by FST testing.
Overall, treated participants experienced a total of 63 treatment-emergent adverse events (TEAE) and 55 were related to the surgical procedure. No serious TEAEs were related to ATSN-101 and while ocular inflammation has been observed, this was infrequent, minimal, and reversible with steroid treatment. These data are up to 6 months post-treatment.
The investigators found that the 9 participants that received high-dose ATSN-101 had a significantly greater change mean from baseline in retinal sensitivity in treated eyes compared with untreated eyes at all time points: days 28 (P = .04), day 56 (P = .01), day 84 (P = .005), and day 168 (P = 0.03). Two patients treated with high-dose ATSN-101 had improvements over 0.3 logMARin best-corrected visual acuity (BCVA), and no treated eyes decreased in BCVA. Four of 5 participants treated with high-dose ATSN-101 and tested with MLMT had either a maximum MLMT score of 6 or at least a 2-level improvement from baseline or compared to the untreated eye at follow-up.
“ATSN-101 continues to be well-tolerated 6 months post-treatment, with no serious adverse events related to the drug. Clinically meaningful improvements in FST and MLMT were observed,” Kay and colleagues concluded.
